sustiva 600mg tablets
bristol-myers squibb pharmaceuticals ltd - efavirenz - tablet - 600mg
viraferonpeg 50microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 50microgram
viraferonpeg 80microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 80microgram
viraferonpeg 120microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 120microgram
viraferonpeg 150microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 150microgram
viraferonpeg 100microgram powder and solvent for solution for injection pre-filled pen clearclick
merck sharp & dohme ltd - peginterferon alfa-2b - powder and solvent for solution for injection - 100microgram
viramune oral suspension
boehringer ingelheim israel ltd. - nevirapine anhydrous (as hemihydrate) - suspension - nevirapine anhydrous (as hemihydrate) 50 mg / 5 ml - nevirapine - nevirapine - for use in combination with other antiretroviral agents for the treatment of hiv-1 infection.
nevirapine 200mg tablets
wockhardt uk limited - nevirapine anhydrous - tablet - 200 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine
daklinza
bristol-myers squibb pharma eeig - daclatasvir dihydrochloride - hepatitis c, chronic - antivirals for systemic use - daklinza is indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults (see sections 4.2, 4.4 and 5.1). for hcv genotype specific activity, see sections 4.4 and 5.1.,
nevirapine wockhardt 400 mg prolonged-release tablets
wockhardt uk limited - nevirapine anhydrous - prolonged-release tablet - 400 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine